5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.60▲ | 0.60▲ | 0.60▲ | 0.58▲ | 0.65▼ |
MA10 | 0.60▲ | 0.60▲ | 0.58▲ | 0.60▲ | 0.78▼ |
MA20 | 0.58▲ | 0.57▲ | 0.57▲ | 0.66▼ | 0.74▼ |
MA50 | 0.59▲ | 0.60▲ | 0.62▼ | 0.80▼ | 1.29▼ |
MA100 | 0.61▼ | 0.64▼ | 0.68▼ | 0.76▼ | 3.63▼ |
MA200 | 0.66▼ | 0.76▼ | 0.83▼ | 1.04▼ | 11.49▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | 0.007▲ | 0.008▲ | -0.001▼ | 0.040▲ |
RSI | 65.149▲ | 60.516▲ | 55.260▲ | 38.241▼ | 36.354▼ |
STOCH | 67.130 | 98.674▲ | 98.145▲ | 25.077 | 6.822▼ |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -59.677 | -94.526▼ |
CCI | 248.862▲ | 70.022 | 81.585 | -30.198 | -81.222 |
Friday, September 12, 2025 07:36 PM
Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.
|
Friday, September 12, 2025 07:36 PM
(GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic ...
|
Friday, September 05, 2025 06:28 AM
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/09/25 | 0.6025 | 0.605 | 0.6025 | 0.605 | 32,486 |
12/09/25 | 0.568 | 0.60 | 0.568 | 0.598 | 194,580 |
11/09/25 | 0.53 | 0.582 | 0.53 | 0.582 | 216,087 |
10/09/25 | 0.5468 | 0.5508 | 0.5302 | 0.539 | 440,769 |
09/09/25 | 0.5517 | 0.5707 | 0.5517 | 0.56 | 230,451 |
08/09/25 | 0.63 | 0.6322 | 0.5616 | 0.5709 | 867,596 |
05/09/25 | 0.6362 | 0.6628 | 0.593 | 0.6265 | 5,046,222 |
04/09/25 | 0.641 | 0.6572 | 0.62 | 0.6327 | 256,932 |
03/09/25 | 0.6356 | 0.6609 | 0.6356 | 0.6483 | 233,031 |
02/09/25 | 0.68 | 0.6844 | 0.65 | 0.662 | 220,965 |
|
|
||||
|
|
||||
|
|